<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985556</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000650368</org_study_id>
    <secondary_id>YONSEI-4-2007-0296</secondary_id>
    <nct_id>NCT00985556</nct_id>
  </id_info>
  <brief_title>Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer</brief_title>
  <official_title>Randomized Phase II Study of S-1 (SOX) or Capecitabine (XELOX) in Combination With Oxaliplatin in Patients With Recurrent or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, S-1, and capecitabine, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor&#xD;
      cells. It is not yet known whether giving oxaliplatin together with S-1 is more effective&#xD;
      than giving oxaliplatin together with capecitabine.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving oxaliplatin together with&#xD;
      S-1 works compared to oxaliplatin given together with capecitabine in treating patients with&#xD;
      recurrent, metastatic, or unresectable gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the time to progression in patients with recurrent or metastatic gastric&#xD;
           cancer treated with oxaliplatin in combination with S-1 vs capecitabine.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess progression-free survival, overall response, disease-control rate,&#xD;
           time-to-treatment failure, response duration, time to response, overall survival,&#xD;
           safety, quality of life, pharmacogenetics, and psychologic distress/coping strategy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2&#xD;
           hours on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as&#xD;
           in arm I.&#xD;
&#xD;
      Courses in both arms repeat every 3 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 2 months for 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tegafur-gimeracil-oteracil potassium</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the stomach&#xD;
&#xD;
          -  Unresectable advanced disease or recurrent disease after resection&#xD;
&#xD;
          -  At least one radiographically documented (CT scan or MRI) measurable or evaluable&#xD;
             lesion in a previously non-irradiated area according to RECIST&#xD;
&#xD;
          -  No clinical evidence of brain metastases or history of other CNS disease unless&#xD;
             adequately treated&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  White blood cell ≥ 4,000/µL&#xD;
&#xD;
          -  ANC ≥ 2,000/µL&#xD;
&#xD;
          -  Platelets ≥ 100,000/µL&#xD;
&#xD;
          -  Bilirubin ≤ 1.25 times upper limit of normal (ULN) (≤ 2.0 times ULN if hepatic&#xD;
             metastasis present)&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  AST/ALT ≤ 3.0 times ULN (≤ 5.0 times ULN if hepatic metastasis present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3.0 times ULN (≤ 5.0 times ULN if bone metastasis present)&#xD;
&#xD;
          -  Must have an intact gastrointestinal tract&#xD;
&#xD;
          -  Able to take oral medications&#xD;
&#xD;
          -  No medically uncontrolled severe infections or complications&#xD;
&#xD;
          -  No prior malignancy other than gastric cancer in the last 5 years except for basal&#xD;
             cell cancer of the skin or preinvasive cancer of the cervix&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No neuropathy ≥ grade 2&#xD;
&#xD;
          -  No clinically relevant heart disease&#xD;
&#xD;
          -  No evidence of past medical history or psychosocial dysfunction that contraindicates&#xD;
             the use of an investigational drug or puts the patient at risk&#xD;
&#xD;
          -  No dementia, altered mental status, or any psychiatric condition that would prohibit&#xD;
             the understanding or rendering of informed consent&#xD;
&#xD;
          -  No uncontrolled hepatitis B or C, chronic liver disease, or diabetes mellitus&#xD;
&#xD;
          -  No other evidence of inappropriate suspicious condition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy for advanced or recurrent disease&#xD;
&#xD;
               -  Prior adjuvant chemotherapy allowed if finished &gt; 6 months before start of study&#xD;
                  treatment&#xD;
&#xD;
          -  No prior therapeutic radiotherapy&#xD;
&#xD;
               -  Prior palliative radiotherapy allowed if it was not done for primary, evaluable,&#xD;
                  or intraabdominal lesions&#xD;
&#xD;
          -  No prior capecitabine or oxaliplatin&#xD;
&#xD;
          -  No other concurrent chemotherapy or radiotherapy (except localized radiotherapy for&#xD;
             pain relief)&#xD;
&#xD;
          -  No concurrent chemically related analogues, such as warfarin, phenytoin, or&#xD;
             allopurinol&#xD;
&#xD;
          -  No concurrent steroid therapy except as follows:&#xD;
&#xD;
               -  Prophylactic use for hypersensitivity control or antiemetic purpose allowed&#xD;
&#xD;
               -  Chronic low dose of steroid (less than methylprednisolone 20 mg or equivalent&#xD;
                  dose) allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun C. Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun C. Chung, MD, PhD</last_name>
      <phone>82-2-2019-3297</phone>
      <email>unchung8@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <last_update_submitted>October 19, 2011</last_update_submitted>
  <last_update_submitted_qc>October 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2011</last_update_posted>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>stage IIIA gastric cancer</keyword>
  <keyword>stage IIIB gastric cancer</keyword>
  <keyword>stage IIIC gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Tegafur</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

